HRA Pharma in licensing deal with PregLem for ulipristal
Paris, France-based HRA Pharma, which is developing medicines and products for women's health and endocrine disease, has entered into a licensing agreement with Swiss firm PregLem for the European development and commercialization of the former's selective progesterone receptor modulator, ulipristal, for the treatment of various benign gynecological disorders.
HRA will retain rights on the product for the rest of the world and will receive payments from PregLem on the achievement of specific development and regulatory milestones, as well as sales royalties.
The French company has already successfully completed a Phase II clinical trial of ulipristal to treat uterine fibroids. PregLem will further develop the compound in this indication by undertaking a pivotal Phase III program in 2008.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze